Fig. 5
From: CDK8/19 inhibition plays an important role in pancreatic β-cell induction from human iPSCs
Generation of iPICs using a non-mutagenic ALK5 inhibitor and CDK8/19 inhibitor instead of mutagenic ALK5iII. a, b Blood glucose (a) and human C-peptide (b) levels after ALK5iII- and SB/Sen-cells (3 × 106 cells/mouse) implantation in diabetic NOD-scid mice. Data are shown as the mean ± SD (n = 4–5 for ALK5iII, n = 3–4 for SB/Sen, n = 1–5 for sham). Unexpected death occurred during the period due to both hyperglycemia and hypoglycemia. All sham mice died by 21 weeks after implantation. Black arrow indicates streptozotocin injection point. c Plasma glucose levels during an oral glucose tolerance test at 21 weeks after implantation. Data are shown as the mean ± SD (ALK5iII-cells; n = 4, SB/Sen-cells; n = 3). d Representative sectional images of grafts 6 months after implantation. Sections were stained with antibodies against insulin (INS), glucagon (GCG) (green/red), and Ki-67/HuN (green/red). Scale bars (white) indicate 0.5 mm